Supportive care in multiple myeloma.
Significant progress in the treatment of multiple myeloma has resulted in improvement of disease control with a trend toward overall and progression-free survival benefit. With the availability of several new therapeutic agents and combinations, a careful emphasis should be placed in the management of disease- and therapy-associated complications. Aggressive management of these complications can impact patients' quality of life as well as treatment outcome. This review highlights some of the critical supportive care measures integral to the optimal care of patients with multiple myeloma.
Chanan-Khan
Asher
A
Roswell Park Cancer Institute, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org
Miller
Kena C
KC
D000740:Anemia / Q000209:etiology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001847:Bone Diseases / Q000209:etiology; D018572:Disease-Free Survival; D005221:Fatigue / Q000209:etiology; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D010166:Palliative Care; D011788:Quality of Life; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal